Phase 2 Type 2 Diabetes Trial, Recruiting NCT07415954 Sponsor: Novo Nordisk A/S Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 2 Type 2 Diabetes Trial, Recruiting

NCT07415954
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were born male or female.
  • People who are between 18 and 75 years old (inclusive) at the time of signing the consent form.
  • People whose blood sugar control measure (called HbA1c) falls within a specific range (7.0–10.0%) as tested by the trial's central laboratory during the screening process.
  • People who are willing to aim for a high level of weight loss — more than 25% of their starting body weight.

Who may not be able to join:

  • People who have taken any medication for diabetes or obesity in the 90 days before screening (with some exceptions: short-term insulin use for up to 14 days in a row, or past insulin use during pregnancy-related diabetes, may be allowed — confirm with trial site).
  • People who have diabetic eye disease (affecting the retina or a part of the eye called the macula) that is not well controlled or may be unstable. An eye examination using pupil-dilating drops is required as part of screening, unless a specific type of non-dilating camera is used (confirm with trial site).
  • People who have a condition where they do not notice the warning signs of low blood sugar, as determined by the investigating doctor using a standard questionnaire.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S

Phone: (+1) 866-867-7178

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
17 April 2026
Est. completion
3 September 2027

Where this trial is recruiting

🇭🇷 Croatia 🇭🇺 Hungary 🇯🇵 Japan 🇵🇱 Poland 🇵🇹 Portugal 🇸🇰 Slovakia 🇰🇷 South Korea 🇪🇸 Spain 🇹🇭 Thailand 🇺🇸 United States

Primary endpoints

Change in glycated haemoglobin (HbA1c) (week 16); Change in HbA1c (week 28); Change in HbA1c (week 40)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov